NewAmsterdam Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . NewAmsterdam Pharma
NAMS Stock   23.67  0.33  1.41%   
NewAmsterdam Pharma financial statements provide useful quarterly and yearly information to potential NewAmsterdam Pharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on NewAmsterdam Pharma financial statements helps investors assess NewAmsterdam Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting NewAmsterdam Pharma's valuation are summarized below:
Gross Profit
45.6 M
Market Capitalization
2.6 B
Enterprise Value Revenue
38.0046
Revenue
45.6 M
Earnings Share
(2.56)
There are over one hundred nineteen available fundamental ratios for NewAmsterdam Pharma, which can be analyzed over time and compared to other ratios. All traders should check NewAmsterdam Pharma's last-minute fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction.

NewAmsterdam Pharma Total Revenue

33.93 Million

Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 17.7 M, Interest Income of 17.7 M or Interest Expense of 0.0, as well as many indicators such as Price To Sales Ratio of 33.94, Dividend Yield of 0.0 or PTB Ratio of 3.36. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.
  
Check out the analysis of NewAmsterdam Pharma Correlation against competitors.
For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.

NewAmsterdam Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets907.9 M864.6 M175.8 M
Slightly volatile
Short and Long Term Debt Total425.6 K448 K8.1 M
Slightly volatile
Other Current Liabilities100.5 M95.7 M14.9 M
Slightly volatile
Total Current Liabilities112.3 M106.9 M28.5 M
Slightly volatile
Property Plant And Equipment Net706.6 K673 K121.7 K
Slightly volatile
Accounts Payable9 M4.7 M3.4 M
Slightly volatile
Cash810.3 M771.7 M156.3 M
Slightly volatile
Non Current Assets Total1.1 M1.2 M5.4 M
Pretty Stable
Cash And Short Term Investments875.9 M834.2 M164.3 M
Slightly volatile
Common Stock Shares Outstanding50.8 M94.4 M28.7 M
Slightly volatile
Liabilities And Stockholders Equity907.9 M864.6 M175.8 M
Slightly volatile
Non Current Liabilities Total191.9 K202 K8.1 M
Slightly volatile
Other Current Assets30.7 M29.2 M6.1 M
Slightly volatile
Total Liabilities112.5 M107.1 M29.8 M
Slightly volatile
Net Invested Capital795.4 M757.5 M154 M
Slightly volatile
Property Plant And Equipment Gross706.6 K673 K127.9 K
Slightly volatile
Short and Long Term Debt9.3 M10.5 M11.4 M
Slightly volatile
Total Current Assets906.6 M863.4 M170.3 M
Slightly volatile
Capital Stock12.8 M13.4 M46.7 M
Slightly volatile
Short Term Debt467.4 K492 K8.1 M
Slightly volatile
Common Stock12.8 M13.4 M46.7 M
Slightly volatile
Property Plant Equipment111.1 K218.5 K64.5 K
Slightly volatile
Current Deferred Revenue8.7 M6 M5 M
Slightly volatile
Other Assets23.9 K25.1 K545.1 K
Slightly volatile
Net Receivables2.3 M1.7 M4.1 M
Slightly volatile
Other Stockholder Equity488 M739.6 M151 M
Slightly volatile
Accumulated Other Comprehensive Income3.9 M4.5 M1.5 M
Slightly volatile
Good Will186.5 K209.8 K228.7 K
Slightly volatile
Intangible Assets507.3 K534 K67.5 M
Slightly volatile

NewAmsterdam Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative74 M70.4 M13 M
Slightly volatile
Selling And Marketing Expenses4.9 M4.7 M1 M
Slightly volatile
Other Operating Expenses124 M221.9 M46.4 M
Slightly volatile
Research Development92.7 M151.4 M34.7 M
Slightly volatile
Total Operating Expenses127 M221.9 M47.4 M
Slightly volatile
Reconciled Depreciation118.7 K113 K23.6 K
Slightly volatile
Cost Of Revenue47.5 K51.1 K24.3 K
Slightly volatile

NewAmsterdam Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow191.8 M340.4 M68 M
Slightly volatile
Depreciation118.7 K113 K23.6 K
Slightly volatile
Capital Expenditures705.6 K672 K98.6 K
Slightly volatile
Total Cash From Financing Activities692.5 M659.5 M120.6 M
Slightly volatile
End Period Cash Flow810.3 M771.7 M156.3 M
Slightly volatile
Change To Liabilities5 M9.5 M3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio33.9453.223111.6933
Slightly volatile
Days Sales Outstanding24.6748.4214.3312
Slightly volatile
Stock Based Compensation To Revenue0.720.73790.2463
Slightly volatile
Capex To Depreciation6.245.94691.875
Slightly volatile
Sales General And Administrative To Revenue1.961.54611.9821
Slightly volatile
Research And Ddevelopement To Revenue4.443.3231.9522
Slightly volatile
Capex To Revenue0.01550.01470.0021
Slightly volatile
Cash Per Share6.338.84073.1436
Slightly volatile
Intangibles To Total Assets6.0E-46.0E-40.1272
Slightly volatile
Current Ratio5.58.07552.94
Slightly volatile
Receivables Turnover7.417.839.0189
Slightly volatile
Capex Per Share0.00750.00710.0015
Slightly volatile
Revenue Per Share0.460.48294.1772
Slightly volatile
Interest Debt Per Share0.00450.00470.458
Slightly volatile
Debt To Assets5.0E-45.0E-40.8679
Slightly volatile
Operating Cycle24.6748.4214.3312
Slightly volatile
Ebt Per Ebit1.751.37051.4559
Slightly volatile
Long Term Debt To Capitalization2.0E-42.0E-43.0E-4
Slightly volatile
Total Debt To Capitalization6.0E-46.0E-40.9924
Slightly volatile
Quick Ratio5.58.07552.9399
Slightly volatile
Net Income Per E B T1.161.01.1011
Pretty Stable
Cash Ratio5.187.21812.732
Slightly volatile
Cash Conversion Cycle24.6748.4214.3312
Slightly volatile
Days Of Sales Outstanding24.6748.4214.3312
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.81.00420.9892
Slightly volatile
Fixed Asset Turnover64.3267.7013557
Slightly volatile
Debt Ratio5.0E-45.0E-40.8679
Slightly volatile
Price Sales Ratio33.9453.223111.6933
Slightly volatile
Asset Turnover0.0990.05270.1584
Slightly volatile

NewAmsterdam Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.3 B2.2 B599.2 M
Slightly volatile

NewAmsterdam Fundamental Market Drivers

Cash And Short Term Investments834.2 M

NewAmsterdam Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
29th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About NewAmsterdam Pharma Financial Statements

NewAmsterdam Pharma shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although NewAmsterdam Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in NewAmsterdam Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on NewAmsterdam Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue6 M8.7 M
Total Revenue45.6 M33.9 M
Cost Of Revenue51.1 K47.5 K
Stock Based Compensation To Revenue 0.74  0.72 
Sales General And Administrative To Revenue 1.55  1.96 
Research And Ddevelopement To Revenue 3.32  4.44 
Capex To Revenue 0.01  0.02 
Revenue Per Share 0.48  0.46 
Ebit Per Revenue(3.87)(4.06)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY